Your browser doesn't support javascript.
loading
Brief Report: Impact of age and SARS-CoV-2 breakthrough infection on humoral immune responses after three doses of COVID-19 mRNA vaccine
Francis M Mwimanzi; Hope R Lapointe; Peter K. Cheung; Yurou Sang; Fatima Yaseen; Rebecca Kalikawe; Sneha Datwani; Laura Burns; Landon Young; Victor Leung; Siobhan Ennis; Chanson J Brumme; Julio S.G. Montaner; Winnie Dong; Natalie Prystajecky; Christopher Fong Jen Lowe; Mari L. DeMarco; Daniel T. Holmes; Janet Simons; Masahiro Niikura; Marc G. Romney; Zabrina L. Brumme; Mark A Brockman.
Afiliação
  • Francis M Mwimanzi; Faculty of Health Sciences, Simon Fraser University, Canada
  • Hope R Lapointe; British Columbia Centre for Excellence in HIV/AIDS, Canada
  • Peter K. Cheung; Faculty of Health Sciences, Simon Fraser University, Canada; British Columbia Centre for Excellence in HIV/AIDS, Canada
  • Yurou Sang; Faculty of Health Sciences, Simon Fraser University, Canada
  • Fatima Yaseen; Faculty of Health Sciences, Simon Fraser University, Canada
  • Rebecca Kalikawe; Faculty of Health Sciences, Simon Fraser University, Canada
  • Sneha Datwani; Faculty of Health Sciences, Simon Fraser University, Canada
  • Laura Burns; Division of Medical Microbiology and Virology, St. Pauls Hospital, Canada
  • Landon Young; Division of Medical Microbiology and Virology, St. Pauls Hospital, Canada
  • Victor Leung; Department of Medicine, University of British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Canada
  • Siobhan Ennis; Faculty of Health Sciences, Simon Fraser University, Canada
  • Chanson J Brumme; British Columbia Centre for Excellence in HIV/AIDS, Canada; Department of Medicine, University of British Columbia, Canada
  • Julio S.G. Montaner; British Columbia Centre for Excellence in HIV/AIDS, Canada; Department of Medicine, University of British Columbia, Canada
  • Winnie Dong; British Columbia Centre for Excellence in HIV/AIDS
  • Natalie Prystajecky; Department of Pathology and Laboratory Medicine, University of British Columbia, Canada; British Columbia Centre for Disease Control Public Health Laboratory, V
  • Christopher Fong Jen Lowe; Division of Medical Microbiology and Virology, St. Pauls Hospital, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Cana
  • Mari L. DeMarco; Division of Medical Microbiology and Virology, St. Pauls Hospital, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Cana
  • Daniel T. Holmes; Division of Medical Microbiology and Virology, St. Pauls Hospital, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Cana
  • Janet Simons; Division of Medical Microbiology and Virology, St. Pauls Hospital, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Cana
  • Masahiro Niikura; Faculty of Health Sciences, Simon Fraser University, Canada
  • Marc G. Romney; Division of Medical Microbiology and Virology, St. Pauls Hospital, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Cana
  • Zabrina L. Brumme; Faculty of Health Sciences, Simon Fraser University, Canada; British Columbia Centre for Excellence in HIV/AIDS, Canada
  • Mark A Brockman; Faculty of Health Sciences, Simon Fraser University, Canada; British Columbia Centre for Excellence in HIV/AIDS, Canada
Preprint em Inglês | medRxiv | ID: ppmedrxiv-22278494
ABSTRACT
BackgroundLonger-term immune response data after three doses of COVID-19 mRNA vaccine remain limited, particularly among older adults and following Omicron breakthrough infection. MethodsWe quantified wild-type- and Omicron-specific serum IgG levels, ACE2 displacement activities and live virus neutralization up to six months post-third dose in 116 adults aged 24-98 years who remained COVID-19-naive or experienced their first SARS-CoV-2 infection during this time. ResultsAmong 78 participants who remained COVID-19-naive throughout follow-up, wild-type- and Omicron BA.1-specific IgG concentrations were comparable between younger and older adults, though BA.1-specific responses were consistently significantly lower than wild-type-specific responses in both groups. Wild-type- and BA.1-specific IgG concentrations declined at similar rates among COVID-19-naive younger and older adults, with median half-lives ranging from 69-78 days. Antiviral antibody function declined substantially over time in COVID-19-naive individuals, particularly older adults by six months, BA.1-specific neutralization was undetectable in 96% of older adults, versus 56% of younger adults. SARS-CoV-2 infection, experienced by 38 participants, boosted IgG levels and neutralization above those induced by vaccination alone. Nevertheless, BA.1-specific neutralization remained significantly lower than wild-type, with BA.5-specific neutralization lower still. ConclusionsOur findings underscore the immune benefits of third COVID-19 mRNA vaccine doses in adults of all ages, but rapid decline of Omicron-specific neutralization activity in COVID-19-naive individuals, particularly among older adults, demonstrates the need for fourth doses within 3-6 months to maintain systemic responses. Individuals who experienced SARS-CoV-2 breakthrough infection post-third vaccine dose however can likely delay a fourth dose beyond this timeframe.
Licença
cc_by_nc_nd
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Cohort_studies / Experimental_studies / Estudo prognóstico / Rct Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Cohort_studies / Experimental_studies / Estudo prognóstico / Rct Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
...